| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.67▼ | 1.68▼ | 1.69▼ | 1.83▼ | 2.03▼ |
| MA10 | 1.67▼ | 1.69▼ | 1.71▼ | 1.91▼ | 2.02▼ |
| MA20 | 1.68▼ | 1.73▼ | 1.82▼ | 2.04▼ | 1.69▼ |
| MA50 | 1.69▼ | 1.83▼ | 1.88▼ | 1.98▼ | 1.16▲ |
| MA100 | 1.72▼ | 1.89▼ | 2.09▼ | 1.61▲ | 2.55▼ |
| MA200 | 1.81▼ | 2.08▼ | 1.98▼ | 1.19▲ | 9.96▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▲ | 0.000▼ | -0.012▼ | -0.055▼ | -0.001▼ |
| RSI | 38.726▼ | 33.015▼ | 31.877▼ | 40.098▼ | 50.215▲ |
| STOCH | 65.556 | 32.200 | 21.135 | 11.130▼ | 45.095 |
| WILL %R | -66.667 | -81.818▼ | -89.831▼ | -97.512▼ | -87.500▼ |
| CCI | -138.348▼ | -68.111 | -88.498 | -111.609▼ | -82.098 |
|
Friday, January 16, 2026 05:44 AM
PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative ColitisCarlsbad, CA, ...
|
|
Wednesday, January 07, 2026 05:31 AM
PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing ...
|
|
Tuesday, December 30, 2025 12:34 AM
PALI-2108 is the first and only PDE4 inhibitor in development targeting the terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) to address ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 16/01/26 | 1.79 | 1.8076 | 1.635 | 1.66 | 9,771,900 |
| 15/01/26 | 1.90 | 1.94 | 1.75 | 1.75 | 6,913,412 |
| 14/01/26 | 1.91 | 2.01 | 1.83 | 1.95 | 4,118,600 |
| 13/01/26 | 1.89 | 1.91 | 1.82 | 1.89 | 2,604,300 |
| 12/01/26 | 1.99 | 1.99 | 1.80 | 1.90 | 7,959,700 |
| 09/01/26 | 1.97 | 2.03 | 1.86 | 1.99 | 5,990,500 |
| 08/01/26 | 1.99 | 2.01 | 1.85 | 1.90 | 4,513,400 |
| 07/01/26 | 2.01 | 2.12 | 1.90 | 2.02 | 9,702,900 |
| 06/01/26 | 2.11 | 2.11 | 1.92 | 1.92 | 3,840,200 |
| 05/01/26 | 2.52 | 2.55 | 2.08 | 2.10 | 7,192,600 |
|
|
||||
|
|
||||
|
|